It is now accepted that drug misuse is a large and growing problem in the United Kingdom, some estimates of the number of regular illicit drug users being as high as three million. The aim of this paper is to provide insight into the methods used to detect drug misuse. The strategy adopted by one laboratory is described and methods of screening for, and identification of, a wide range of compounds are provided. No claim is made that this is the best approach or that the list of drugs detected is comprehensive; the range of drugs encountered is always increasing and the lists are constantly updated. It is hoped that users of toxicology laboratory services will gain an appreciation of the capabilities and limitations of the techniques available; and that those who may wish to provide such a service will find the necessary information in a readily accessible format. (J Clin Pathol 1999;52:713-718) 
The only way to establish the limits of what is possible is to test the boundaries of the impossible.
Why look for drugs of abuse?
For hundreds, indeed thousands of years, the use of chemicals for recreational or religious purposes has been part of most cultures. Even in Victorian Britain, laudanum and opium were used by respectable members of society, and cocaine was readily available in preparations such as Vin Mariani and the original Coca-Cola. More widely within Western society, the use of alcohol and nicotine as an aid to relaxation and social discourse has been generally accepted, apart from the abortive attempt by the government of the USA to impose prohibition of alcohol through the Eighteenth Amendment to the Constitution in the first half of this century.
Ever since the early days of a modern youth culture in the late 1950s and early 1960s the use of stronger drugs for recreation has been developed. These chemicals include illicit preparations such as heroin, Ecstasy (3, MDMA) , and cocaine (as the hydrochloride, or as free base: "crack"). In addition to these illicit compounds various drugs intended for medical use have been "adopted" into misuse. In particular the benzodiazepines (diazepam and temazepam) are widely misused, as are opiates including diamorphine (heroin) and dihydrocodeine. Ketamine, methadone, tricyclic antidepressants, and dextropropoxyphene are further examples of prescribed drugs encountered in individuals who have not been prescribed them. The casual use of these drugs may never be a problem and is, for many, a natural part of recreational activity. The use of these drugs becomes a problem only if the individual involved becomes a habitual user and suVers longer term physical problems (illness and infections) and psychological problems which make them unable to be fully active and productive members of society.
The statistics of drug addicts notified to the United Kingdom Home OYce (London: Government Statistical Service) give some evidence of the continued growth in the use of drugs of abuse (at a rate greater than 10% per annum) as measured by the number of addicts notified to the Home OYce and by the number of drug seizures. The statistics for numbers of abusers only include those seeking help from statutory bodies and give no indication of the overall number of users. A more meaningful indication of the scale of the problem comes from calculations made by Atha and Blanchard (in preparation for publication) to be found on the internet site of the Institute for the Study of Drug Dependence (http://www.isdd.co.uk): the estimated number of regular drug users in the United Kingdom has increased from approximately 1 million in 1982/84 to 2.5-3 million in 1995.
Drug abuse has eVects not only on the user but on the whole of society. This can take the form of crime related to the acquisition of drugs, and danger to other members of society resulting from the modification of the behaviour of drug users, who may become dangerous or irresponsible. Drug abuse will also cause an increased risk of the spread of transmittable diseases not only between addicts but also into associated populations.
The circumstances in which screening for drugs of abuse may be required are diverse. A request may be made by casualty departments simply to exclude the presence of drugs in a patient who has been admitted unconscious, with a decreased level of consciousness, or displaying bizarre behaviour. In most situations the demonstration of the presence of a drug which the patient should not be taking is suYcient. However, in a minority of cases it may be necessary to perform quantification in order to establish the degree of clinical eVect of the drug and this will present a problem which must be considered by any potential service providers.
Clinics oVering support and advice to drug addicts are widespread and include drug dependency units, community drug teams, and outreach services. These require regular drug checks on their clients in order to establish appropriate further treatment and they provide the most significant demands for the routine toxicology laboratory.
Finally, though rarely encountered in the past, screening for drugs of abuse is now increasingly performed both as a prerequisite before employment and randomly during employment.
In all of the situations outlined above some control of sample integrity is desirable, but in the case of employment screening it is imperative, as the consequences of an incorrect result have far reaching consequences. Chain of custody documentation must be used and the samples (in duplicate, one to be tested and one to remain sealed to be used in the event of a problem-usually a challenged positive finding) must be in tamper proof containers.
What sample to use?
If we were interested in monitoring therapeutic drugs we would, in most cases, wish to monitor concentrations present in the blood of the patient and relate the results to established therapeutic windows. However, in cases of drug misuse our interest is primarily in establishing their presence and identity, and analysis of blood is not generally used.
In very acute cases, vomitus or stomach washings may be useful if there is evidence that the drug has been taken orally. In some situations sweat may be screened for drugs of abuse (as is proposed in the case of roadside testing by the police) but limitations in the amount of sample available for further procedures restrict the value of this approach. There are also published methods for hair analysis, particularly where a longer term assessment of drug use is desired; such analyses are, in our experience, diYcult and outside the remit of a routine laboratory.
Drugs are usually recognised by the body as being foreign and not capable of being utilised, and are rapidly processed for excretion. In general they may be found readily in urine either in their original state (sometimes at concentrations as much as 100 times that found in blood), or in a conjugated form or as metabolites. Furthermore, because of the ease of obtaining a urine sample, the longer time scale for detection, and the ease of analysis owing to the practical absence of proteins, urine has proved to be the sample of choice for illicit drug screening, and a random urine sample in a plain 20 ml container is adequate. StaV involved in obtaining samples in the employment screening or clinic situation should be made aware that sample substitution by drug misusers (the use of a more "appropriate" urine sample from the clients/patients point of view) is relatively common.
Some liaison with the members of staV involved in obtaining the sample can be desirable, especially as they can often be junior medical staV faced with a possible drug addict for the first time. In addition, because a screen for drugs is open ended (it is never possible to prove the absence of all drugs) it is useful to be given a clear indication as to whether the presence of any particular substance or group of substances is suspected.
The initial screen
Commercially prepared immunoassay systems are now widely available for initial screening of urine samples. These include EMIT (the enzyme multiplied immunoassay technique), for instance the Dade-Behring system (Walton Manor, Milton Keynes, UK), FPIA (fluorescent polarisation immunoassay) oVered by Abbott (Maidenhead, UK), and chemiluminescence oVered by DPC (Immulite) (DPC, Llanberis, UK). A simple though expensive "dipstick" system supplied by Roche (Welwyn Garden City, UK), "Ontrak", uses the principle of microparticle capture inhibition to provide a screen for use within clinics, and the introduction of similar systems for roadside testing (using samples of perspiration) has been proposed. The microparticle capture inhibition system is also available in a more economical version for use within the laboratory (Roche Cobas/Integra).
The instrumentation that may be used ranges from simple dedicated machines, such as the Dade-Behring ETS, to more generally used machines, such as Olympus or Roche analysers.
Our experience has been with the DadeBehring EMIT system using the ETS dedicated system; therefore the following description is based upon our experience with this. Our initial screen is for a panel consisting of opiates, methadone, amphetamines, barbiturates, benzodiazepines, cocaine metabolite, and cannabinoids. The ETS is simply calibrated using calibration standards provided at three levels: negative, cut oV, and high. Samples which display activity below the cut oV are designated negative and those that display activity above the cut oV are designated positive. The concentration of drug which is used as the cut oV level has been selected to provide optimal detection of positives while minimising the generation of false positives which may occur with any immunoassay screening system. We also carry out a screen for ethanol. This could be performed with the ETS using an alcohol dehydrogenase based method but we choose to use head space analysis as this allows screening for some volatile compounds (table  1) , though for solvent abuse screening a blood sample will usually oVer greater sensitivity, and other analyses (such as measurement of hippuric acid/creatinine ratios in the urine) may prove necessary. The method as a screen for alcohol is simple. Into a 10 ml tube which has a septum in the cap put 200 µl of sample (or standard) and add 200 µl of internal standard (propan-1-ol, 4000 mg/litre in water), mix, and incubate at 60°C for 10 minutes. Using a gas tight syringe, inject 1 ml of vapour into a gas chromatography system with a Chromosorb 101 (100/120 mesh) packing and flame ionisation detection. We use a 1.5 m column and an oven temperature of 125°C.
A wide screen for basic drugs is provided by using a Hewlett-Packard gas chromatography/ mass selective detector (GCMS) bench top system, consisting of a 5890 series II gas chromatograph with a 5971A mass selective detector. The extraction used has been described previously 1 : into a 1.5 ml microtube take 0.6 ml of sample and add 50 µl of concentrated ammonia (specific gravity 0.88) plus 200 µl of butyl acetate. This is mixed vigorously for 30 seconds and then spun in a microfuge for five minutes, after which 3 µl from the upper layer are injected into the GCMS system. The column used is a Hewlett-Packard HP-5 capillary 25 metres in length with an internal diameter 0.32 mm and 0.17 µm film thickness. The gas chromatography conditions used are initial temperature 85°C, initial time 1.5 minutes, rate 10°C/min, final temperature 280°C, and final time of nine minutes, giving a run time of approximately 30 minutes. The mass spectrometry conditions are scan range 40-500 and solvent delay 2.5 minutes.
Using this system we are able to screen for a the wide range of drugs indicated in tables 2 and 3. It is possible to use this method to screen for many of the commonly encountered abused/misused drugs, though this list should not be regarded as comprehensive and it is constantly being updated. To investigate unknown peaks detected during a run we use both a commercial library (Pfleger, Maurer and Weber: MS and GC data of drugs and poisons, available from VCH (UK) Ltd, Cambridge, UK) and our own library.
Secondary tests
Under this heading are included assays which arise from our initial findings. In considering the results of the immunoassay screens we will deal with each screen in turn.
In the case of opiates it is necessary to confirm the presence and the identity of the drugs. We use a system of solid phase extraction followed by propionylation (SPE/ MS), and a report on this has been published elsewhere. 2 The presence of methadone does not usually require confirmation, but if it is requested the basic extraction described above is suitable. It is not unknown for addicts who have been prescribed methadone to sell it on and then adulterate their urine sample using a small portion of the prescribed methadone in order to achieve a positive finding when tested. Such adulteration is readily confirmed by performing the basic extraction and establishing the absence of the cyclic methadone metabolite.
The presence of "amphetamines" requires confirmation and identification, and we have described one approach elsewhere. 2 However, in many cases the basic extraction will suYce, as may be noted from table 2.
One problem with the Dade-Behring "amphetamine class" screen is the cross reaction with a whole range of non-amphetamines, particularly lofepramine metabolites, putrefaction products, and trazodone. Lofepramine metabolites and products of putrefaction such as benzenethanamine may be detected by using the basic extraction system as described above. Trazodone will be detected by using the SPE/MS propionylation system as described for opiates (relative retention time for propionylated trazodone, 0.975; major ions 166, 56, 252) .
The presence of barbiturates in a sample is usually a result of the presence of phenobarbitone (phenobarbital), though other barbiturates may still be encountered. We generally use a simple acid extraction to confirm and identify barbiturates but have noticed improved sensitivity with ether extraction followed by methylation. Briefly, for a more sensitive screen for barbiturates, take 500 µl of urine and 500 µl of 0.1 M phosphate buVer pH 6.5, and add 25 µl of internal standard (Proadifen-SKF 525a, 100 mg/litre in methanol) and 8 ml of ether; after mixing for 10 minutes the phases are separated by centrifugation and the ether layer taken and evaporated to dryness. To the dry extract is added 70 µl of DMSO/TMAH (dimethyl sulphoxide/tetramethyl ammonium hydroxide, 20:1) and this is mixed for 30 seconds; 10 µl of iodomethane are then added and after brief mixing this is incubated for five minutes at room temperature. After methylation add 200 µl of 0.1 M hydrochloric acid and 1 ml of hexane to the tube and mix for two minutes using a vortex mixer. After allowing the layers to separate, take the hexane layer and dry it down. The resulting mixture is reconstituted in 100 µl of hexane and 3 µl are injected onto the GC/MS using the conditions described above for the basic extracts. We present our data for methylated barbiturates in table 4.
The presence of benzodiazepines and cocaine in urine does not normally require confirmation. The presence of benzodiazepines may be confirmed using a scaled up basic extraction (2.5 ml of urine, 200 ml of ammonia, 2 ml butyl acetate, and 25 µl of SKF 525a internal standard). Varian also publish a solid phase extraction method for benzodiazepines using their BondElut Certify columns which we have used with some success (available from Phenomenex, Macclesfield, UK).
The detection of the presence of cocaine is straightforward: the simple basic extraction is adequate for the detection of cocaine and the ecgoninemethylester metabolite (the second most dominant metabolite of cocaine). Though the immunoassay system is directed against benzoylecgonine (the major cocaine metabolite), this compound is not readily detected using a routine screening system. However, our experience has been that confirmation of a putative immunoassay positive finding has always been possible by searching for cocaine and ecgoninemethylester (the second most abundant cocaine metabolite) alone.
Positive cannabinoid results are not usually confirmed, though confirmation is required in cases where the implications of such a finding will be far reaching (for example, an isolated positive finding in a juvenile). We use a GC/MS method which has proved to be both reliable and sensitive. The method, described by Kemp et al, 3 involves hydrolysis to yield THC acid (11-nor-9-carboxy-9 -tetrahydrocannabinol), which is then extracted and derivatised to form the trimethylsilyl derivative which may be detected using GC/MS.
Tertiary tests
There are certain drugs that are not easily detected as they are normally present in very low concentrations, for which the only convenient systems of analyses are specific immunoassays. In the case of LSD (lysergic acid diethylamide) there are other methods available (high pressure liquid chromatography with fluorimetric detection) but these are best regarded as reference methods rather than for routine use. Buprenorphine (Temgesic) and fentanyl are two other occasionally encountered drugs for which a specific immunoassay is the most convenient screening method.
Also within this category are compounds which are unsuitable for gas chromatography owing to their physical characteristics (high molecular weight, non-volatile, or highly polar molecules). No doubt the simpler to use and less expensive liquid chromatography/mass spectrometry systems now coming onto the market will facilitate the provision of a much better service with respect to these compounds. 
